JP2020512974A5 - - Google Patents

Info

Publication number
JP2020512974A5
JP2020512974A5 JP2019552613A JP2019552613A JP2020512974A5 JP 2020512974 A5 JP2020512974 A5 JP 2020512974A5 JP 2019552613 A JP2019552613 A JP 2019552613A JP 2019552613 A JP2019552613 A JP 2019552613A JP 2020512974 A5 JP2020512974 A5 JP 2020512974A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
independently
pharmaceutically acceptable
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019552613A
Other languages
English (en)
Japanese (ja)
Other versions
JP7154221B2 (ja
JP2020512974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/025562 external-priority patent/WO2018183956A1/en
Publication of JP2020512974A publication Critical patent/JP2020512974A/ja
Publication of JP2020512974A5 publication Critical patent/JP2020512974A5/ja
Application granted granted Critical
Publication of JP7154221B2 publication Critical patent/JP7154221B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019552613A 2017-03-30 2018-03-30 Hpk1の阻害剤としてのナフチリジン Active JP7154221B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/078792 2017-03-30
CN2017078792 2017-03-30
CN2018076909 2018-02-15
CNPCT/CN2018/076909 2018-02-15
PCT/US2018/025562 WO2018183956A1 (en) 2017-03-30 2018-03-30 Naphthyridines as inhibitors of hpk1

Publications (3)

Publication Number Publication Date
JP2020512974A JP2020512974A (ja) 2020-04-30
JP2020512974A5 true JP2020512974A5 (enExample) 2022-06-08
JP7154221B2 JP7154221B2 (ja) 2022-10-17

Family

ID=62223184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019552613A Active JP7154221B2 (ja) 2017-03-30 2018-03-30 Hpk1の阻害剤としてのナフチリジン

Country Status (12)

Country Link
US (2) US10407424B2 (enExample)
EP (1) EP3601284B1 (enExample)
JP (1) JP7154221B2 (enExample)
KR (1) KR20190136028A (enExample)
CN (1) CN110678466B (enExample)
AU (1) AU2018244935A1 (enExample)
BR (1) BR112019018093A2 (enExample)
CA (1) CA3052492A1 (enExample)
IL (1) IL268262A (enExample)
MX (1) MX2019011511A (enExample)
TW (1) TW201904964A (enExample)
WO (1) WO2018183956A1 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110678466B (zh) * 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
WO2019062803A1 (zh) * 2017-09-28 2019-04-04 基石药业 作为a2a受体抑制剂的并环类衍生物
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
JP7386842B2 (ja) * 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト ナフチリジン化合物およびその使用
WO2020069402A1 (en) * 2018-09-30 2020-04-02 Genentech, Inc. Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) * 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US20220047603A1 (en) 2018-12-11 2022-02-17 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
TW202102488A (zh) 2019-03-26 2021-01-16 比利時商健生藥品公司 Hpk1抑制劑
MA55478A (fr) 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs bicycliques de hpk1
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
WO2021004535A1 (en) * 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Cinnolines as inhibitors of hpk 1
US12459958B2 (en) 2019-07-17 2025-11-04 Beone Medicines I Gmbh Tricyclic compounds as HPK1 inhibitor and the use thereof
CN110483402B (zh) * 2019-08-12 2021-07-23 上海毕得医药科技股份有限公司 一种3-溴-5-苯基-1h-吡唑的合成方法
US12673933B2 (en) 2019-08-21 2026-07-07 Beone Medicines I Gmbh Aminopyrazine compounds as HPK1 inhibitor and the use thereof
US12215105B2 (en) * 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN113336747A (zh) * 2020-03-03 2021-09-03 轶诺(浙江)药业有限公司 新型hpk1抑制剂及其制备方法和应用
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ, インコーポレイテッド Cd73阻害性2,4-ジオキソピリミジン化合物
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
CN111965367A (zh) * 2020-07-23 2020-11-20 北京大学第三医院(北京大学第三临床医学院) Hip-55在作为gpcr偏向药物靶点中的应用
WO2022064458A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
WO2022167627A1 (en) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Map4k1 inhibitors
CN114907375B (zh) * 2021-02-07 2026-03-31 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
CN114907374B (zh) * 2021-02-07 2026-03-10 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117295737A (zh) 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN115073308A (zh) * 2021-03-15 2022-09-20 苏州信礼发医药技术有限公司 1-氨甲基-1-环丙醇的合成方法
US20240226106A1 (en) * 2021-03-17 2024-07-11 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
TW202304434A (zh) * 2021-04-08 2023-02-01 大陸商杭州阿諾生物醫藥科技有限公司 一種高活性的hpk1激酶抑制劑
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
WO2022222951A1 (zh) * 2021-04-22 2022-10-27 浙江海正药业股份有限公司 芳香稠合环类衍生物及其制备方法和用途
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2024000751A (es) * 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023193759A1 (en) * 2022-04-07 2023-10-12 Insilico Medicine Ip Limited Hpk1 antagonists and uses thereof
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2023294765A1 (en) * 2022-06-17 2024-12-12 Sundance Biosciences, Inc. Kinase modulators and methods of use thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024003773A1 (en) * 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
JP2025531158A (ja) * 2022-09-21 2025-09-19 武田薬品工業株式会社 シクロプロパンカルボン酸の合成
CN119894905A (zh) * 2022-09-23 2025-04-25 广州威诺森医药科技有限公司 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN101821279A (zh) 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2770998B1 (en) * 2011-10-27 2020-04-29 Merck Sharp & Dohme Corp. Factor ixa inhibitors
RU2627712C2 (ru) * 2012-06-15 2017-08-10 Кьюрдженикс Инк. Соединение как ингибитор передачи сигналов wnt, его композиции и применение
JP2016518328A (ja) * 2013-03-12 2016-06-23 キュアジェニックス インコーポレイテッド 癌治療のための化合物
RS61919B1 (sr) 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
CN110678466B (zh) * 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类

Similar Documents

Publication Publication Date Title
ES2761406T3 (es) Protección transitoria de células normales durante una quimioterapia
RU2468021C2 (ru) Гетероциклические соединения и их применение
JP2024532733A5 (enExample)
JP2020007311A5 (enExample)
JP2026000916A5 (enExample)
JP2021523099A5 (enExample)
JP2016513737A5 (enExample)
JP2019510798A5 (enExample)
RU2014130125A (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
RU2019102647A (ru) Антипролиферационные средства на основе пиримидина
RU2021102253A (ru) Деструкторы белка mdm2
JP2021532162A5 (enExample)
JP2022507065A5 (enExample)
JP2011251990A5 (enExample)
JP2015520143A5 (enExample)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
RU2012144844A (ru) Комплексные соединения железа(iii) для лечения и профилактики симптомов железодефицита и железодефицитной анемии
RU2020118594A (ru) Противораковые агенты
JP2012158602A5 (enExample)
RU2018122864A (ru) Ингибиторы протеинкиназ, их способ получения и медицинское применение
JP2024505562A (ja) 選択的bcl-xl protac化合物及び使用の方法
JP2008506644A5 (enExample)
UA129653C2 (uk) Макроциклічна сполука як агоніст sting, спосіб з її застосуванням і шлях її застосування
JP2019514955A (ja) 選択的エストロゲン受容体ダウンレギュレーター(serds)
JP2021522197A5 (enExample)